Sunday 23 October

IW1  10.30–11.30 Industry Workshop  Carron Room
     11.30–12.00 Break

WS1  12.00–13.30 Case Study Session  Clyde Auditorium

In collaboration with the University of Liverpool Drug Interactions website: www.hiv-druginteractions.org

WS1CH 12.00–12.10 Welcome and update on DDI websites
       Saye Khoo

WS11 12.10–12.35 Long-acting ARVs for PrEP
      Ian McGowan, University of Pittsburgh, Pittsburgh, USA

WS12 12.35–13.00 Case 1: managing multiple co-morbidities
      Presenter: Sally Jewsbury, Central Manchester NHS Foundation Trust, Manchester, UK
      Discussant: Marta Boffito, St Stephen’s AIDS Trust, Chelsea and Westminster Hospital, London, UK

WS13 13.00–13.25 Case 2: more than just ARVs and chemotherapy
      Presenter: Alessia Dalla Pria, Chelsea and Westminster Hospital, London, UK
      Discussant: Fiona Marra, Gartnavel Hospital, Glasgow, UK

WS1CH 13.25–13.30 Closing remarks
       Saye Khoo

13.30–14.30 Lunch  Congress Exhibition Hall (Hall 4)

SS1  14.30–16.00 Industry Symposium  Clyde Auditorium
     16.00–16.30 Coffee  Congress Exhibition Hall (Hall 4)
     16.30–16.45 Official Opening  Clyde Auditorium
      Andrew Phillips, University College London, UK
      Welcome from Glasgow City
      Bailie Marie Garrity, Glasgow City Council, Glasgow, UK

16.45–17.30 Joep Lange and Jacqueline van Tongeren Memorial Lecture  Clyde Auditorium
      Lecture dedicated to Joep Lange and Jacqueline van Tongeren in recognition of their commitment and passion to rid the world of HIV/AIDS

16.45–16.55 Introduction
      Catherine Hankins, Amsterdam Institute for Global Health and Development, University of Amsterdam, Amsterdam, The Netherlands
**SCIENTIFIC PROGRAMME** (continued)

| KL1 | 16.55–17.30 | Ending the HIV/AIDS pandemic: follow the science |
|     |             | Anthony S Fauci, National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH), Bethesda, USA |

| KL | 17.30–18.30 | Keynote Lectures |
|    |             | Clyde Auditorium |
| KLCH |             | Co-Chairs: Catherine Hankins, Andrew Phillips |

| KL2 | 17.30–18.00 | Treatment for cancer, HIV and viral hepatitis in Europe using low cost generic drugs: what could be done? |
|     |             | Andrew Hill, St Stephen’s AIDS Trust, Chelsea and Westminster Hospital, London, UK |

| KL3 | 18.00–18.30 | Revolution in prevention in low and middle income settings |
|     |             | Linda-Gail Bekker, The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa, and President, International AIDS Society (IAS) |

| O11 | 08.45–10.45 | Antiretrovirals: Progress and Remaining Challenges |
|     |             | Clyde Auditorium |
| O11CH |             | Co-Chairs: Kevin M de Cock, Division of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Nairobi, Kenya, Cristina Mussini, University of Modena and Reggio Emilia, Infectious Disease Clinic, Modena, Italy |

| 08.45–09.30 | Lock Lecture |
|             | Clyde Auditorium |
| 08.45–08.50 | Lock Lecture: introduction |
|             | David Galloway, President, Royal College of Physicians and Surgeons of Glasgow, Glasgow, UK |
| O111 | 08.50–09.30 | Lock Lecture: HIV treatment as prevention: from a research hypothesis to a new global target and beyond |
|     |             | Julio Montaner, British Columbia Centre for Excellence in HIV/AIDS, and University of British Columbia, Vancouver, Canada |
| O112 | 09.30–09.50 | Initiation of ART early in HIV infection: START to finish |
|     |             | Jens D Lundgren, CHIP and PERSIMUNE, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark |
| O113 | 09.50–10.10 | Transition to adult care |
|     |             | Pablo Rojo, Paediatric Infectious Diseases, Hospital 12 de Octubre, Complutense University, Madrid, Spain |

**Monday 24 October**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10.10–10.25 | Persistent disparities in meeting WHO/UNAIDS targets for ART coverage and ART-induced HIV RNA suppression across Europe  
  Kamilla Grønborg Laut, CHIP, Centre for Health and Infectious Disease Research, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark |
| 10.25–10.45 | Panel discussion                                                        |
| 10.45–11.15 | Coffee  Congress Exhibition Hall (Hall 4)                                |
| 11.15–12.30 | **Treatment Strategies**                                                |
| O12CH     | Co-Chairs: Christine Katlama, Pitié-Salpêtrière Hospital, Paris, France  
  Daniel R Kuritzkes, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA |
| O121*     | Simplification to atazanavir/ritonavir + lamivudine versus maintaining  
  atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-infected patients: 96-week data of the ATLAS-M trial  
  Roberta Gagliardini, Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy |
| O122*     | Dual therapy with a boosted protease inhibitor plus lamivudine is an  
  effective maintenance strategy in patients on second-line antiretroviral therapy in Africa: the ANRS 12286/MOBIDIP trial  
  Laura Ciaffi, UMI 233, IRD INSERM, Montpellier, France |
| O123*     | Resistance profile analysis of treatment-experienced HIV-1-infected patients switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV)  
  Christian Callebaut, Clinical Virology, Gilead Sciences, Foster City, USA (Industry Speaker†) |
| O124*     | Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks  
  Chloe Orkin, Department of Infection and Immunity, Royal London Hospital, Barts Health NHS Trust, London, UK |
| O125*     | Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults  
  Francois Raffi, Infectious and Tropical Diseases, CHU de Nantes, Nantes, France |
| 12.30–14.00 | Scientific Posters and Lunch                                            |
| 12.45–13.45 | Antiretroviral Therapy: Efficacy and Adverse Events: Poster Discussion Session |
Durability and tolerability of first-line combination including two NRTI and RAL or ATV/r or DRV/r in patients enrolled in the ICONA Foundation cohort
Antonella d’Arminio Monforte, Department of Health Sciences, Clinic of Infectious and Tropical Diseases, University of Milan, Milan, Italy

Efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed-dose combination (FDC) compared with ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive women with HIV-1 infection (ARIA study): subgroup analyses
Margaret Johnson, Centre for HIV Medicine, Royal Free Hospital, London, UK

Psychiatric adverse events from the DTG ART-naive phase 3 clinical trials
Romina Quercia, Research and Development, ViiV Healthcare, Brentford, UK (Industry Speaker†)

Multicentre open-label pilot study of switching from efavirenz to dolutegravir for central nervous system (CNS) toxicity
Nicole Pagani, St Stephen’s AIDS Trust, Chelsea and Westminster Hospital, London, UK (Industry Speaker†)

Tryptophan metabolism and its relationship with central nervous system toxicity in subjects switching from efavirenz to dolutegravir
Michael Keegan, HIV Research Unit, Clinical Trials Centre, Imperial College London, and ViiV Healthcare Ltd, London, UK (Industry Speaker†)

High rates of multi-class drug resistance in HIV-1-infected individuals monitored with CD4 cell count in Uganda
Amrei von Braun, College of Health Sciences, Infectious Diseases Institute, Makerere University, Kampala, Uganda

Ageing and Cancer: Lomond Auditorium
Poster Discussion Session

Co-Chairs: Caroline Sabin, Department of Infection and Population Health, University College London, London, UK
Andrew Winter, NHS Greater Glasgow and Clyde, Glasgow, UK

Ageing and the evolution of co-morbidities among HIV patients in the EuroSIDA cohort
Sara Lopes, Health Economics and Outcomes Research, Gilead Sciences, London, UK (Industry Speaker†)

The extent of B-cell activation and dysfunction preceding lymphoma development
Alvaro Borges, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark

Future challenges for clinical care of an ageing population infected with HIV: a ‘geriatric HIV’ modelling study
Davide De Francesco, Department of Infection and Population Health, University College London, London, UK
P156 13.15–13.25  Quantifying the future clinical burden of an ageing HIV-positive population in Italy: a mathematical modelling study  
Mikaela Smit, Department of Infectious Disease Epidemiology, Imperial College London, London, UK

P153 13.25–13.35  Health-related costs in chronic HIV infection: a case-control study versus general population using a claims-based approach in Germany  
Eva Wolf, Clinical Research, MUC Research, Munich, Germany

P190 13.35–13.45  Survival in HIV-1-infected individuals with diagnosis of lymphoma compared to general population: data from ICONA Foundation cohort  
Antonella Cingolani, Infectious Diseases, Catholic University, Rome, Italy

CS1 14.00–15.30  Challenging Cases in HIV: Interactive Case Study Session  
In collaboration with the International Antiviral Society-USA (IAS-USA)

CS1CH  
Co-Chairs: Pedro Cahn, Fundacion Huesped, Juan A Fernandez Hospital, Buenos Aires, Argentina  
Peter Reiss, Academic Medical Center, University of Amsterdam and HIV Monitoring Foundation, Amsterdam, The Netherlands

CS11 14.00–14.30  Case 1: antiretroviral therapy (ART) strategies: choosing an initial regimen  
Roy M Gulick, Weill Cornell Medicine, New York, USA

CS12 14.30–15.00  Case 2: management of HIV infection in the heavily treatment-experienced patient  
Ian Williams, Department of Infection and Population Health, University College London, London, UK

CS13 15.00–15.30  Case 3: implementation and issues in pre-exposure prophylaxis (PrEP)  
Jean-michel Molina, Saint-Louis Hospital and University of Paris, Paris, France

CS13PL  
Panel: Pedro Cahn  
Roy M Gulick  
Jean-michel Molina  
Peter Reiss  
Ian Williams

O13 15.30–17.00  Keeping the Patient in the Centre of Quality Care: What Matters?  
In collaboration with the International AIDS Society (IAS)

O13CH  
Co-Chairs: Linda-Gail Bekker  
Anton Pozniak, St Stephen’s Centre, Chelsea and Westminster NHS Trust, London, UK, and Governing Council, IAS

O13CH 15.30–15.35  Welcome, introduction and setting the scene  
Linda-Gail Bekker
**Confidentiality matters: innovative HIV testing**
Cheryl Johnson, World Health Organization (WHO), Geneva, Switzerland

**Convenience matters: catalogue STI testing and PrEP**
Patrick S Sullivan, Rollins School of Public Health, Emory University, Atlanta, USA

**Context matters: one stop medical care from Eastern Europe to downtown London**
Jeffrey V Lazarus, CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Barcelona, Spain

**Choice matters: differentiated models of care**
Helen Bygrave, SAMU (Southern Africa Medical Unit), Médecins Sans Frontières (MSF), Cape Town, South Africa

**Clients matter: listening to the voices of people living with HIV**
Kevin Osborne, HIV Programmes and Advocacy, IAS, Geneva, Switzerland

**Panel discussion and closing remarks**
Led by Anton Pozniak

**Coffee**
Congress Exhibition Hall (Hall 4)

**Industry Symposium**
Clyde Auditorium

**Tuesday 25 October**

SS3 08.30–10.00 **Industry Symposium** Clyde Auditorium

10.00–10.30 **Coffee** Congress Exhibition Hall (Hall 4)

O21 10.30–12.15 **Co-morbidities and HIV Management** Clyde Auditorium

O21CH Co-Chairs: Lene Ryom, Department of Infectious Diseases and Rheumatology, CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Juan-Sierra Madero, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico

O211 10.30–10.50 **Helping the HIV physician through the challenges of co-morbidities** Edouard Battegay, Center of Competence Multimorbidity, University Hospital Zurich, Zurich, Switzerland

O212* 10.50–11.05 **HIV patients today and 10 years ago: do they have the same needs?** Results from cross-sectional analysis of ANRS CO3 Aquitaine cohort Charles Cazanave, Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

*Please see pages 20–25 for full author details of oral papers.
### SCIENTIFIC PROGRAMME (continued)

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>O213*</td>
<td>11.05–11.20</td>
<td>Long-term impact of lipodystrophy on the risk of morbidity and mortality: a 20-year longitudinal cohort study</td>
<td>Esteban Martinez, Infectious Diseases Unit, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain</td>
</tr>
<tr>
<td>O214*</td>
<td>11.20–11.35</td>
<td>Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients</td>
<td>Michael Sabranski, Infectious Diseases, ICH Study Center Hamburg, Hamburg, Germany</td>
</tr>
<tr>
<td>O215*</td>
<td>11.35–11.50</td>
<td>Cognitive function and depression in HIV-positive individuals and matched controls</td>
<td>Davide De Francesco</td>
</tr>
<tr>
<td></td>
<td>11.50–12.15</td>
<td>Panel discussion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12.15–13.45</td>
<td>Scientific Posters and Lunch</td>
<td>Congress Exhibition Hall (Hall 4)</td>
</tr>
<tr>
<td>CoS1</td>
<td>12.30–13.35</td>
<td>Apps and New Technologies in the Management of HIV Infection: Community Session</td>
<td>Clyde Auditorium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In collaboration with the European AIDS Treatment Group (EATG)</td>
<td></td>
</tr>
<tr>
<td>CoS1CH</td>
<td></td>
<td>Co-Chairs: Lisa Power, Potestatis.com, Cardiff, UK</td>
<td>Alain Volny-Anne, Bangkok, Thailand</td>
</tr>
<tr>
<td>CoS1CH</td>
<td>12.30–12.35</td>
<td>Welcome and introduction</td>
<td>Lisa Power and Alain Volny-Anne</td>
</tr>
<tr>
<td>CoS11</td>
<td>12.35–12.45</td>
<td>New approaches and new technologies to improve access to HIV testing</td>
<td>Teymur Noori, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden</td>
</tr>
<tr>
<td>CoS12</td>
<td>12.45–12.55</td>
<td>How can we start HIV treatment very soon after HIV diagnosis? Can technology help?</td>
<td>Tarandeep Anand, The Thai Red Cross AIDS and Research Center, Bangkok, Thailand</td>
</tr>
<tr>
<td>CoS14</td>
<td>13.05–13.15</td>
<td>Use of medical apps and privacy issues: should we be worried about confidentiality?</td>
<td>François Houÿez, European Organisation for Rare Diseases (EURORDIS), Paris, France</td>
</tr>
<tr>
<td></td>
<td>13.15–13.35</td>
<td>Panel discussion and close</td>
<td></td>
</tr>
<tr>
<td>O22</td>
<td>13.45–15.30</td>
<td>Co-infections and Malignancies</td>
<td>Clyde Auditorium</td>
</tr>
<tr>
<td>O22CH</td>
<td></td>
<td>Chair: Jürgen Rockstroh, HIV Outpatient Clinic, University of Bonn, Bonn, Germany</td>
<td></td>
</tr>
</tbody>
</table>

*Please see pages 20–25 for full author details of oral papers.*
**HCV therapies: what have we achieved and remaining challenges?**
Andri Rauch, Bern University Hospital and University of Bern, Bern, Switzerland

**HPV-associated malignancies in HIV**
Deborah Konopnicki, Infectious Diseases, CHU Saint-Pierre, Brussels, Belgium

**Screening for malignancies: what is new?**
Jean-Philippe Spano, University Institute of Oncology (IUC)/University Pierre and Marie CURIE (UPMC)/Pitié-Salpêtrière Hospital, Paris, France

**Differences in virological and immunological risk factors for non-Hodgkin lymphoma (NHL) and Hodgkin (HL): the D:A:D study**
Leah Shepherd, Research Department of Infection and Population, University College London, London, UK

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.45–14.05</td>
<td><strong>O221</strong> HCV therapies: what have we achieved and remaining challenges? Andri Rauch, Bern University Hospital and University of Bern, Bern, Switzerland</td>
</tr>
<tr>
<td>14.05–14.25</td>
<td><strong>O222</strong> HPV-associated malignancies in HIV Deborah Konopnicki, Infectious Diseases, CHU Saint-Pierre, Brussels, Belgium</td>
</tr>
<tr>
<td>14.25–14.45</td>
<td><strong>O223</strong> Screening for malignancies: what is new? Jean-Philippe Spano, University Institute of Oncology (IUC)/University Pierre and Marie CURIE (UPMC)/Pitié-Salpêtrière Hospital, Paris, France</td>
</tr>
<tr>
<td>14.45–15.00</td>
<td><strong>O224</strong> Differences in virological and immunological risk factors for non-Hodgkin lymphoma (NHL) and Hodgkin (HL): the D:A:D study Leah Shepherd, Research Department of Infection and Population, University College London, London, UK</td>
</tr>
</tbody>
</table>

**Critical Issues in Eastern and Central Europe Including MDR TB and Hepatitis Co-infection**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.30–17.00</td>
<td><strong>O23</strong> Critical Issues in Eastern and Central Europe Including MDR TB and Hepatitis Co-infection Clyde Auditorium In collaboration with the European AIDS Clinical Society (EACS)</td>
</tr>
<tr>
<td>15.30–15.35</td>
<td><strong>O23CH</strong> Welcome and introduction Manuel Battegay</td>
</tr>
<tr>
<td>15.35–15.55</td>
<td><strong>O231</strong> MDR or XDR TB: a case study from Eastern Europe Cristiana Oprea</td>
</tr>
<tr>
<td>15.55–16.20</td>
<td><strong>O232</strong> Feedback on the highlights of the TB2016 conference in Durban in July 2016 Jan Fehr, University Hospital of Zurich, Zurich, Switzerland</td>
</tr>
<tr>
<td>16.20–16.40</td>
<td><strong>O233</strong> Tackling the HCV epidemic in the EECA region: a physician’s perspective Nikoloz Chkhartishvili, Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia</td>
</tr>
<tr>
<td>16.40–17.00</td>
<td><strong>O23PL</strong> Moderated panel discussion (TB and HCV co-infection) and closing remarks Panel members to include the above and joined by: Justyna Kowalska, Medical University of Warsaw, Warsaw, Poland Jürgen Rockstroh</td>
</tr>
</tbody>
</table>

**Coffee** Congress Exhibition Hall (Hall 4)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.00–17.30</td>
<td><strong>SS4</strong> Industry Symposium Clyde Auditorium</td>
</tr>
</tbody>
</table>

**Poster Reception** Congress Exhibition Hall (Hall 4)
**SCIENTIFIC PROGRAMME (continued)**

**Wednesday 26 October**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30–10.45</td>
<td>PrEP in High Income Settings</td>
<td>In collaboration with the British HIV Association (BHIVA)</td>
<td>Clyde Auditorium</td>
</tr>
<tr>
<td>O31</td>
<td>Co-Chairs:</td>
<td>Chloe Orkin, Department of Infection and Immunity, Royal London</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospital, Barts Health NHS Trust, London, UK, and Chair, BHIVA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Simon Collins, HIV i-Base, London, UK</td>
<td></td>
</tr>
<tr>
<td>08.30–08.50</td>
<td>Update on the evidence for PrEP effectiveness</td>
<td>Sheena McCormack, Medical Research Council (MRC) Clinical Trials Unit, University College London, London, UK</td>
<td>Clyde Auditorium</td>
</tr>
<tr>
<td>O311</td>
<td>Brief overview of cost-effectiveness of PrEP</td>
<td>Valentina Cambiano, University College London, London, UK</td>
<td>Clyde Auditorium</td>
</tr>
<tr>
<td>08.50–09.05</td>
<td>Lessons from implementation in France</td>
<td>Jean-michel Molina</td>
<td>Clyde Auditorium</td>
</tr>
<tr>
<td>O312</td>
<td>Utilisation of emtricitabine/tenofovir (FTC/TDF) for HIV pre-exposure prophylaxis in the USA by gender (2013–1Q2016)</td>
<td>Keith Rawlings, Medical Affairs, Gilead Sciences, Foster City, USA (Industry Speaker†)</td>
<td>Clyde Auditorium</td>
</tr>
<tr>
<td>O315*</td>
<td>Implementation strategies across Europe: an overview</td>
<td>Teymur Noori</td>
<td>Clyde Auditorium</td>
</tr>
<tr>
<td>O316</td>
<td>PrEP implementation from the community perspective</td>
<td>Bruno Spire, French National Institute for Medical Research (INSERM), and AIDES, Pantin, France</td>
<td>Clyde Auditorium</td>
</tr>
<tr>
<td>11.15–12.15</td>
<td>The Way Forward</td>
<td>Impranil Phanupak, Thai Red Cross AIDS Research Center, Bangkok, Thailand</td>
<td>Clyde Auditorium</td>
</tr>
<tr>
<td>O32</td>
<td>Co-Chairs:</td>
<td>Ian Wellar, University College London, London, UK</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Immunoology of HIV persistence: implications for the development of a cure</td>
<td>Steven G Deeks, University of California, San Francisco, USA</td>
<td>Clyde Auditorium</td>
</tr>
<tr>
<td>O321</td>
<td>Where next for ARVs?</td>
<td>Roy M Gulick</td>
<td></td>
</tr>
<tr>
<td>10.45–11.15</td>
<td>Coffee</td>
<td></td>
<td>Congress Exhibition Hall (Hall 4)</td>
</tr>
<tr>
<td>O322</td>
<td></td>
<td></td>
<td>Clyde Auditorium</td>
</tr>
</tbody>
</table>

†Please see pages 20–25 for full author details of oral papers.
†Industry Speakers presenting are not in accordance with the EACCME rules. Therefore, the EACCME is unable to grant credit for these specific presentations.
12.15–13.30 Scientific Posters and Lunch

12.30–13.10 Renal and Bone: Poster Discussion Session Clyde Auditorium

<table>
<thead>
<tr>
<th>PCH</th>
<th>12.30–12.40</th>
<th>Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir</th>
<th>Jose Gatell, Infectious Diseases Unit, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCH</td>
<td>12.40–12.50</td>
<td>Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV co-infected individuals in sub-Saharan Africa: results from the HEPIK cohort</td>
<td>Veronica Miller, Forum for Collaborative HIV Research, UC Berkeley School of Public Health, Washington DC, USA</td>
</tr>
<tr>
<td>P169</td>
<td>12.50–13.00</td>
<td>The relative impact of antiretroviral drugs and baseline immune status on bone quality in HIV-positive subjects: results from the HIV UPBEAT cohort</td>
<td>Giovanni Villa, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK</td>
</tr>
<tr>
<td>P093</td>
<td>13.00–13.10</td>
<td>Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) versus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent</td>
<td>Tara McGinty, School of Medicine/HIV Molecular Research Group, University College Dublin, Dublin, Ireland</td>
</tr>
</tbody>
</table>

12.30–13.20 Pharmacokinetics and Drug Interactions: Poster Discussion Session Lomond Auditorium

<table>
<thead>
<tr>
<th>PCH</th>
<th>12.30–12.40</th>
<th>Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations in routine care of HIV-infected children with diverse ethnic origin</th>
<th>David Cooper, The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCH</td>
<td>12.40–12.50</td>
<td>Efavirenz significantly decreases etonogestrel exposure: results of a bidirectional pharmacokinetic evaluation of efavirenz- and nevirapine-based antiretroviral therapy plus etonogestrel contraceptive implants</td>
<td>Patrick Mallon, School of Medicine, University College Dublin, Dublin, Ireland</td>
</tr>
<tr>
<td>P031</td>
<td>12.30–12.40</td>
<td>Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations in routine care of HIV-infected children with diverse ethnic origin</td>
<td>Sandra Soeria-Atmadja, Division of Pediatrics, Karolinska Institutet, CLINTEC, Stockholm, Sweden</td>
</tr>
<tr>
<td>P302</td>
<td>12.40–12.50</td>
<td>Efavirenz significantly decreases etonogestrel exposure: results of a bidirectional pharmacokinetic evaluation of efavirenz- and nevirapine-based antiretroviral therapy plus etonogestrel contraceptive implants</td>
<td>Catherine Chappell, Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, USA</td>
</tr>
</tbody>
</table>
SCIENTIFIC PROGRAMME (continued)

P094 12.50–13.00 Population pharmacokinetics (PK) of dolutegravir (DTG) alone and following treatment switch
Laura Dickinson, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK

P142 13.00–13.10 Low rifampicin and isoniazid concentrations are associated with delayed sputum conversion in HIV-positive patients co-infected with tuberculosis in Uganda
Christine Sekaggya, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda

P301 13.10–13.20 Interactions between HIV and HCV therapies: how common and who wins?
Adele Torkington, North West ID Unit, North Manchester General Hospital, Manchester, UK

O33 13.30–15.00 Antiretroviral Strategies and New Drugs Clyde Auditorium

O33CH Co-Chairs: Sean Emery, The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
Ian Williams

O331* 13.30–13.45 Non-inferiority of dual-therapy (DT) with darunavir/ritonavir (DRV/r) plus 3TC versus triple-therapy (TT) with DRV/r plus TDF/FTC or ABC/3TC for maintenance of viral suppression: 48-week results of the DUAL-GESIDA 8014 trial
José Arribas, HIV Unit, Hospital La Paz, IdiPAZ, Madrid, Spain

O332* 13.45–14.00 French national survey of resistance to integrate inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS-AC11 virology network)
Anne-Genevieve Marcelin, Department of Virology, Pitie-Salpetriere Hospital, Paris, France

O333* 14.00–14.15 Switching from cART to dolutegravir (DTG) maintenance monotherapy in virologically suppressed HIV-1-infected adults: a randomised, multicentre, non-inferiority clinical trial (DOMONO)
Bart Rijnders, Internal Medicine, Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands

O334* 14.15–14.30 Subgroup analyses from ONCEMRK, a phase 3 study of raltegravir (RAL) 1200 mg once daily versus RAL 400 mg twice daily, in combination with tenofovir/emtricitabine, in treatment-naïve HIV-1-infected subjects
Pedro Cahn

and

O335B* 14.30–14.45 HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 96 safety analysis
Cyril Llamoso, Research and Development, ViiV Healthcare, Wallingford, USA (Industry Speaker†)

*Please see pages 20–25 for full author details of oral papers.
†Industry Speakers presenting are not in accordance with the EACCME rules. Therefore, the EACCME is unable to grant credit for these specific presentations.
O336* 14.45–15.00 Efficacy and safety of long-acting HIV fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV-1: interim 48-week results from the randomised, controlled, phase 3, non-inferiority TALENT study
Dong Xie, Research and Development, Frontier Biotechnologies Co, Nanjing, China (Industry Speaker†)

15.00–15.15 Congress Closing Remarks Clyde Auditorium

Giulio Corbelli, European AIDS Treatment Group (EATG), Brussels, Belgium, and Bologna, Italy
Andrew Phillips

*Please see pages 20–25 for full author details of oral papers.
†Industry Speakers presenting are not in accordance with the EACCME rules. Therefore, the EACCME is unable to grant credit for these specific presentations.
Submitted abstracts accepted for oral presentation within the main programme, including full author group and affiliations

Sunday 23 October

O114 Persistent disparities in meeting WHO/UNAIDS targets for ART coverage and ART-induced HIV RNA suppression across Europe

Kamilla Grønborg Laut¹; Leah Shepherd²; Roxana Rado³; Igor Karpov⁴; Milosz Parczewski⁵; Cristina Mussini⁶; Fernando Maltez⁷; Marcelo Losso⁸; Nikoloz Chkhartishvili⁹; Hila Elinav¹⁰; Helen Kovari¹; Anders Blaxhult¹²; Robert Zangerle¹³; Tatiana Trofimora¹⁴; Brygida Krysz¹⁵; Kai Zilmer¹⁶; Elena Kuzovatova¹⁷; Therese Staub¹⁸; Dorte Råben¹; Jens Lundgren²; Amanda Mocroft³; Ole Kirk⁴

¹Department of Infectious Diseases, CHIP, Centre for Health and Infectious Disease Research, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; ²Department of Infection and Population Health, University College London, London, UK; ³Spitalul de Boli Infectioase si Tropical, Dr Victor Babes Hospital, Bucharest, Romania; ⁴Department of Infectious Diseases, Belarus State Medical University, Minsk, Belarus; ⁵Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University, Szczecin, Poland; ⁶Department of Infectious and Tropical Diseases, University of Modena and Reggio Emilia, Modena, Italy; ⁷Servicio de Doencas Infecciosas, Hospital de Curry Cabral, Lisbon, Portugal; ⁸Servicio de Immunocomprometidos, Hospital JM Ramos Mejia, Buenos Aires, Argentina; ⁹Department of Infectious Diseases, AIDS & Clinical Immunology Research Center, Tbilisi, Georgia; ¹⁰Department of Clinical Microbiology and Infectious Diseases, Hadassah Hospital, Jerusalem, Israel; ¹¹Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, Zürich, Switzerland; ¹²Department of Infectious Diseases, Södersjukhuset, Stockholm, Sweden; ¹³Department of Dermatology and Venerology, Medical University Innsbruck, Innsbruck, Austria; ¹⁴Department of Infectious Diseases, Novgorod Centre for AIDS Prevention and Control, Velikij Novgorod, Russian Federation; ¹⁵Department of Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland; ¹⁶Centre of Infectious Diseases, West-Tallin Central Hospital, Tallin, Estonia; ¹⁷Privolzhsky Federal District AIDS Control and Prevention Center, Nizhny Novgorod Scientific and Research Institute of Epidemiology and Microbiology named after Academician IN Blokhina, Nizhny Novgorod, Russian Federation; ¹⁸Service des Maladies Infectieuses, Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg

O121 Simplification to atazanavir/ritonavir + lamivudine versus maintaining atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-infected patients: 96-week data of the ATLAS-M trial

Roberta Gagliardini¹; Massimiliano Fabbiani¹; Eugenia Quiros Roldan²; Alessandra Latin²; Gabriella D’Ettorre³; Andrea Antinori³; Antonella Castagna⁴; Giancarlo Orofino⁵; Daniela Francisci⁶; Pierangelo Chinello⁷; Giordano Madeddu⁸; Stefano Rusconi⁹; Barbara Del Pin¹⁰; Annalisa Mondi¹¹; Alberto Borghetti¹¹; Emanuele Focà¹²; Manuela Colafalda¹³; Roberto Cauda¹; Simona Di Giambenedetto¹⁴; Andrea De Luca¹⁵

¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy; ²Division of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy; ³Department of Infectious Dermatology and Allergology, IFO San Gallicano Institute (IRCCS), Rome, Italy; ⁴Department of Infectious Diseases, La Sapienza University, Rome, Italy; ⁵Department of Infectious Diseases, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy; ⁶Department of Infectious and Tropical Diseases, Vita-Salute San Raffaele University, San Raffaele Hospital, Milan, Italy; ⁷Infectious and Tropical Diseases Unit, Amedeo di Savoia Hospital, Turin, Italy; ⁸Infectious Diseases Clinic, University of Perugia, Perugia, Italy; ⁹Systemic Infections and Immunodeficiency Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy; ¹⁰Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy; ¹¹Division of Infectious Diseases, Santa Caterina Novella Hospital, Galatina, Italy; ¹²Infectious Disease Unit, Istituto di Scienze Biomediche e Cliniche, Luigi Sacco, University of Milan, Milan, Italy; ¹³Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy; ¹⁴Infectious Dermatology and Allergology Unit, IFO San Gallicano Institute (IRCCS), Rome, Italy; ¹⁵Infectious Diseases Unit, Siena University Hospital, Siena, Italy
**O122** Dual therapy with a boosted protease inhibitor plus lamivudine is an effective maintenance strategy in patients on second-line antiretroviral therapy in Africa: the ANRS 12286/MOBIDIP trial

Laura Ciaffi1; Sinata Koulla-Shiro2; Adrien Sawadogo3; N Fatou Ngom Gueye4; Vincent Le Moing1; Sabrina Eyermann-Duvernoy1; Suzanne Izard1; Jacques Zoungrana3; Pretty Mbouyap5; Mamadou Diallo6; Guillaume Bado3; Koumba Toure Kane7; Avelin Aghokeng8; Martine Peeters1; Jacques Reynes9; Eric Delaporte1

1UMI 233, IRD INSERM, Montpellier, France; 2Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon; 3Hôpital de Jour, Centre Hospitalier Universitaire de Soro, Sancou, Bobo Dioulasso, Burkina Faso; 4Hôpital de Jour, Centre Hospitalier Universitaire de Fann, Dakar, Senegal; 5Projet MOBIDIP, Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (Cameroon Site), Yaounde, Cameroon; 6CRCF, Centre Hospitalier Universitaire de Fann, Dakar, Senegal; 7Laboratoire de Bactériologie-Virologie, Centre Hospitalier Universitaire Aristide Le Dantec, Dakar, Senegal; 8Centre de Recherche sur les Maladies Infectieuses et, Virology Laboratory IMPM-IRD, Yaounde, Cameroon; 9Maladies Infectieuses, Centre Hospitalier Universitaire Montpellier, Montpellier, France

**O123** Resistance profile analysis of treatment-experienced HIV-1-infected patients switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV)

Nicolas Margot1; Renee Ram1; Moupali Das2; Marshall Fordyce2; Scott McCallister2; Michael Miller1; Christian Callebaut1

1Department of Clinical Virology, Gilead, Foster City, USA; 2Department of Clinical Research, Gilead, Foster City, USA

**O124** Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks

Chloe Orkin1; Edwin DeJesus2; Moti Ramgopal2; Gordon Crofoot4; Peter Ruane2; Anthony LaMarca6; Anthony Mills5; Bernard Van der Cam9; Joseph De Wet3; Jurgen Rockstroh10; Adriano Lazzarin11; Bart Rijnders12; Daniel Podzamczer12; Anders Thalme14; Marcel Stoeckle15; Danielle Porter16; Hui Liu17; Andrew Cheng18; Erin Quirk18; Devi SenGupta18; Huyen Cao18

1Department of Infection and Immunity, Royal London Hospital, Barts Health NHS Trust, London, UK; 2Private Practice, Orlando Immunology Center, Orlando, USA; 3Research Facility, Midway Immunology and Research Center, Fort Pierce, USA; 4Research Facility, The Crofoot Research Center, Houston, USA; 5Private Practice, Peter Jerome Ruane, Los Angeles, USA; 6Research Facility, Therafirst Medical Center, Fort Lauderdale, USA; 7Private Practice and Research Facility, Mills Clinical Research, Los Angeles, USA; 8Department of Internal Medicine, Cliniques Universitaires St Luc, Brussels, Belgium; 9Private Practice, Dr Joseph J de Wet, Vancouver, Canada; 10Department of Medicine, Bonn University Hospital, Bonn, Germany; 11Dipartimento di Malattie Infettive, Ospedale San Raffaele, Milan, Italy; 12Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands; 13AIDS Unit in Infectious Diseases Service, Hospital Universitari de Bellvitge, Barcelona, Spain; 14Department of Medicine, Division of Infectious Diseases, Karolinska University Hospital, Huddinge, Stockholm, Sweden; 15Clinic of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland; 16Department of Clinical Virology, Gilead Sciences, Inc, Foster City, USA; 17Department of Biostatistics – HIV, Gilead Sciences, Inc, Foster City, USA; 18Department of Clinical Research – HIV, Gilead Sciences, Inc, Foster City, USA
O125 Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults
Francois Raffi1; Chloe Orkin2; Amanda Clarke3; Laurence Slama4; Joel Gallant5; Eric Daar6; Mingjin Yan7; Michael E Abram8; Sandra Frigborg9; Andrew Cheng10; Martin Rhee10
1Department of Infectious and Tropical Diseases, CHU de Nantes, Nantes, France; 2Department of Infection and Immunity, Barts Health NHS Trust, London, UK; 3HIV Unit, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK; 4Department of Infectious and Tropical Diseases, Hôpital Tenon, Paris, France; 5Specialty Services, Southwest Care Center, Santa Fe, USA; 6Division of Adult Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, USA; 7Department of Biostatistics – HIV, Gilead Sciences, Foster City, USA; 8Department of Clinical Virology, Gilead Sciences, Foster City, USA; 9Department of Clinical Operations – HIV, Gilead Sciences, Foster City, USA; 10Department of Clinical Research – HIV, Gilead Sciences, Foster City, USA

O212 HIV patients today and 10 years ago: do they have the same needs? Results from cross-sectional analysis of ANRS CO3 Aquitaine cohort
Fabrice Bonnet1; Fabien Le Marec2; Olivier Leleux3; Charles Cazanave3; Estibaliz Lazaro1; Pierre Duffau1; Marie-Anne Vandenheede1; Patrick Mercie1; Didier Neau3; François Dabis3
1Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; 2INSERM U1219, Université de Bordeaux, ISPED, Bordeaux, France; 3Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

O213 Long-term impact of lipodystrophy on the risk of morbidity and mortality: a 20-year longitudinal cohort study
Gemma Sanchez; Ana Gonzalez-Cordon; Jhon Rojas; Jose Blanco; Jordi Blanch;Montserrat Lonca; Berta Torres; Maria Martinez- Rebollar; Montserrat Laguna; Amparo Tricas; Ana Rodriguez; Josep Mallolas; Jose Gatell; Judit Peñafiel; Elisa de Lazzari; Esteban Martinez
Infectious Diseases Unit, Hospital Clinic-Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain

O214 Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
Michael Sabranski1; Christoph Wyen2; Christian Hoffmann1; Tanya Welz3; Michael Kolb2; Eva Wolf3; Hans-Juergen Stellbrink1
1Department of Infectious Diseases, ICH Study Center Hamburg, Hamburg, Germany; 2Department of Infectious Diseases, Praxis am Ebertplatz, Cologne, Germany; 3Department of Infectious Diseases, MUC Research, Munich, Germany

O215 Cognitive function and depression in HIV-positive individuals and matched controls
Davide De Francesco1; Jonathan Underwood2; Marta Boffito3; Frank Post4; Patrick Malloni5; Jaime Vera6; Ian Williams1; Jane Anderson1; Margaret Johnson6; Caroline Sabin1; Alan Winston2
1Department of Infection and Population Health, University College London, London, UK; 2Division of Infectious Diseases, Imperial College London, London, UK; 3Pharmacokinetic Research Unit, Chelsea and Westminster Hospital, London, UK; 4HIV Research Centre, King’s College Hospital, London, UK; 5School of Medicine, University College Dublin, Dublin, Ireland; 6Lawson Unit, Brighton and Sussex Medical School, Brighton, UK; 7Centre for the Study of Sexual Health and HIV, Homerton University Hospital, London, UK; 8HIV/AIDS Services, Royal Free Hospital, London, UK
Differences in virological and immunological risk factors for non-Hodgkin lymphoma (NHL) and Hodgkin (HL): the D:A:D study

Leah Shepherd1; Lene Ryom2; Matthew Law3; Camilla Hatleberg4; Stephane de Wit5; Antonella d’Arminio Monforte6; Manuel Battegay7; Andrew Phillips1; Fabrice Bonnet8; Peter Reiss9; Christian Pradier10; Andrew Grulich3; Caroline Sabin1; Jens Lundgren9; Amanda Mocroft1

1Department of Infection and Population Health, University College London, London, UK; 2Department of Infectious Diseases, Section 2100, CHRP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 3The Kirby Institute, University of New South Wales, Sydney, Australia; 4Division of Infectious Diseases, Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium; 5Dipartimento di Scienze della Salute, Clinica di Malattie Infective e Tropicali, Azienda Ospedaliera-Polo Universitario San Paolo, Milan, Italy; 6Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland; 7CHU de Bordeaux and INSERM U997, Université de Bordeaux, Talence, France; 8Division of Infectious Diseases, Academic Medical Centre, University of Amsterdam, and Department of Global Health, HIV Monitoring Foundation, Amsterdam, The Netherlands; 9Department of Public Health, Nice University Hospital, Nice, France

Utilisation of emtricitabine/tenofovir (FTC/TDF) for HIV pre-exposure prophylaxis in the USA by gender (2013–1Q2016)

Staci Bush1; Keith Rawlings1; David Magnuson2; Patty Martin3; Olga Lugo-Torres4; Robertino Mera-Giler5

1Department of Medical Affairs, Gilead Sciences, Foster City, USA; 2Drug Safety and Public Health, Gilead Sciences, Foster City, USA; 3Department of Epidemiology, Gilead Sciences, Foster City, USA

InterPrEP: internet-based pre-exposure prophylaxis (PrEP) with generic tenofovir DF/emtricitabine (TDF/FTC) in London: analysis of pharmacokinetics, safety and outcomes

Xinzhu Wang1; Nneka Nwokolo2; Roxanna Korologou-Linden1; Andrew Hill3; Gary Whitlock2; Isaac Day-Weber3; Myra McClure1; Marta Boffito2

1Faculty of Medicine, Imperial College London, London, UK; 2Chelsea and Westminster Hospital, London, UK; 3St Stephen’s AIDS Trust, Chelsea and Westminster Hospital, London, UK

Non-inferiority of dual-therapy (DT) with darunavir/ritonavir (DRV/r) plus 3TC versus triple-therapy (TT) with DRV/r plus TDF/FTC or ABC/3TC for maintenance of viral suppression: 48-week results of the DUAL-GESIDA 8014 trial

Federico Pulido1; Esteban Ribera2; Maria Lagarde3; Ignacio Pérez-Valero4; Jesús Santos4; José Iribarren5; Antonio Payeas6; Pere Domingo7; José Sanz8; Miguel Cervero9; Adrian Curran9; Francisco Rodríguez10; María Téllez11; Pablo Ryan12; Pilar Barrufet13; Hernando Knobel14; Antonio Rivero15; Belén Alejos16; María Yllescas16; José Arrilas17; Study Group GESIDA-8014-DUAL17

1HIV Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; 2Servicio de Enfermedades Infecciosas, Hospital Vall d’Hebron, Barcelona, Spain; 3HIV Unit, Hospital La Paz, IDIAPAZ, Madrid, Spain; 4Unidad de Enfermedades Infecciosas, Hospital Virgen de la Victoria, Málaga, Spain; 5Servicio de Enfermedades Infecciosas, Hospital Donostia, San Sebastián, Spain; 6Servicio de Medicina Interna, Hospital Son Llatzer, Palma de Mallorca, Spain; 7Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 8Servicio de Medicina Interna, Hospital Princep de Asturias, Alcalá de Henares, Spain; 9Servicio de Medicina Interna, Hospital Severo Ochoa, Leganés, Spain; 10Unidad de Enfermedades Infecciosas, Hospital Infantil Elena Huelva, Huelva, Spain; 11Servicio de Medicina Interna, Hospital Clinicó San Carlos, Madrid, Spain; 12Servicio de Medicina Interna, Hospital Infanta Leonor, Madrid, Spain; 13Servicio de Medicina Interna, Hospital de Mataró, Mataró, Spain; 14Servicio de Enfermedades Infecciosas, Hospital del Mar, Barcelona, Spain; 15Sección de Enfermedades Infecciosas, Hospital Reina Sofia, Córdoba, Spain; 16Fundación de Investigación, SEIMC-GESIDA, Madrid, Spain; 17GESIDA-8014-DUAL Study Group, Spain
French national survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS-AC11 virology network)

Anne-Genevieve Marcelin1; Maxime Grude2; Charlotte Charpentier3; Pantxika Bellcave4; Audrey Rodallec5; Coralie Pallier6; Stephanie Raymond7; Audrey Mirand8; Laurence Bocket9; Laurence Morand-Joubert10; Constance Delaugerre11; Brigitte Montes12; Helene Jeulin13; Thomas Mourez14; Samira Fafi-Kremer15; Corrine Amiel16; Catherine Roussel17; Julia Dina18; Marie-Anne Trabaud19; Helene Le Guillou-Guillemette20; Sophie Valet21; Anne Signori-Schmuck22; Anne Maillard23; Anne Krivine24; Philippe Flandre2; Diane Descamps3; Vincent Calvez1

1Department of Virology, Pitie-Salpetriere Hospital, Paris, France; 2Inserm U1136, Pitie-Salpêtrière Hospital, Paris, France; 3Department of Virology, Bichat Hospital, Paris, France; 4Department of Virology, Bordeaux Hospital, Bordeaux, France; 5Department of Virology, Nantes Hospital, Nantes, France; 6Department of Virology, Paul Brousse Hospital, Paris, France; 7Department of Virology, Toulouse Hospital, Paris, France; 8Department of Virology, Clermont-Ferrand Hospital, Clermond-Ferrand, France; 9Department of Virology, Lille Hospital, Lille, France; 10Department of Virology, Saint Antoine, Paris, France; 11Department of Virology, Saint Louis Hospital, Paris, France; 12Department of Virology, Montpellier Hospital, Montpellier, France; 13Department of Virology, Nancy Hospital, Nancy, France; 14Department of Virology, Rouen Hospital, Rouen, France; 15Department of Virology, Strasbourg Hospital, Strasbourg, France; 16Department of Virology, Tenon Hospital, Paris, France; 17Department of Virology, Amiens Hospital, Amiens, France; 18Department of Virology, Caen Hospital, Caen, France; 19Department of Virology, Lyon Hospital, Lyon, France; 20Department of Virology, Angers Hospital, Angers, France; 21Department of Virology, Brest Hospital, Brest, France; 22Department of Virology, Grenoble Hospital, Grenoble, France; 23Department of Virology, Rennes Hospital, Rennes, France; 24Department of Virology, Cochin Hospital, Paris, France

Switching from cART to dolutegravir (DTG) maintenance monotherapy in virologically suppressed HIV-1-infected adults: a randomised, multicentre, non-inferiority clinical trial (DOMONO)

Ingeborg Wijting1; Casper Rokx1; Charles Boucher2; Jeroen Van Kampen3; Dorine De Vries-Sluijs3; Karin Schurink4; Hannelore Bax5; Maarten Derksen5; Elrozy Andrinopoulou6; Ineke Van der Ende7; Eric Van Gorp8; Jan Nouwen9; Annelies Verbon10; Wouter Bierman11; Bart Rijnders1

1Department of Internal Medicine, Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands; 2Department of Virology, Erasmus MC, Rotterdam, The Netherlands; 3Department of Biostatistics, Erasmus MC, Rotterdam, The Netherlands; 4Department of Internal Medicine, Infectious Diseases, Universitair Medisch Centrum Groningen, Groningen, The Netherlands

Subgroup analyses from ONCERMK, a phase 3 study of raltegravir (RAL) 1200 mg once daily versus RAL 400 mg twice daily, in combination with tenofovir/emtricitabine, in treatment-naïve HIV-1-infected subjects

Pedro Cahn1; Richard Kaplan2; Paul Sax3; Kathleen Squires4; Jean-michel Molina5; Anchalee Avihingsanon6; Winai Ratanausawan7; Evelyn Rojas8; Mohammed Bassool8; Xia Xu9; Anthony Rodgers10; Sandy Rawlins10; Bach-Yen Nguyen10; Randi Leavitt10; Hedy Teppler10

1Juan A Fernandez Hospital, Fundacion Huesped, Buenos Aires, Argentina; 2Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa; 3Brigham and Women’s Hospital, Harvard Medical School, Boston, USA; 4Department of Infectious Diseases, Thomas Jefferson University, Philadelphia, USA; 5Hospital Saint-Louis, University of Paris Diderot, Paris, France; 6Medical Department, HIV-NAT Research Collaboration, Bangkok, Thailand; 7Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 8Department of Infectious Diseases, Cericap Multiclinicas, Guatemala City, Guatemala; 9Helen Joseph Hospital, University of Witwatersrand, Johannesburg, South Africa; 10Department of Research, Merck & Co, Inc, Kenilworth, USA
O335A  HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 96 subgroup analysis

Enrique Rafael Granados-Reyes1; Louis Sloan2; Jerome Ernst3; Mey León4; David Stock5; Cyril Llamoso6; Samit Joshi6; George Hanna7; Max Lataillade6

1Centro de Investigación Clínica Gramel SC, Mexico City, Mexico; 2Research Department, North Texas Infectious Diseases Consultants, Dallas, USA; 3AIDS Community Research Initiative of America, New York, USA; 4Department of Infectious and Tropical Diseases, Asociacion Civil Impacta Salud y Educacion, Lima, Peru; 5Department of Research and Development, Bristol-Myers Squibb, Wallingford, USA; 6Department of Research and Development, ViiV Healthcare, Wallingford, USA; 7Department of Research and Development, Bristol-Myers Squibb, Princeton, USA

O335B  HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 96 safety analysis

Cyril Llamoso1; Johannes Bogner2; Larissa Afonina3; Mey León4; Alexey Yakovlev5; David Stock6; Samit Joshi6; George Hanna7; Max Lataillade1

1Department of Research and Development, ViiV Healthcare, Wallingford, USA; 2Section for Infectious Diseases, Hospital of the University of Munich, Med IV, Munich, Germany; 3Clinical Research and Medical Information, Republic Hospital of Infectious Diseases, St Petersburg, Russian Federation; 4Department of Infectious and Tropical Diseases, Asociacion Civil Impacta Salud y Educacion, Lima, Peru; 5Department of Infectious Diseases, St Petersburg Botkin Clinical Infectious Diseases Hospital, St Petersburg, Russian Federation; 6Department of Research and Development, Bristol-Myers Squibb, Wallingford, USA; 7Department of Research and Development, Bristol-Myers Squibb, Princeton, USA

O336  Efficacy and safety of long-acting HIV fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV-1: interim 48-week results from the randomised, controlled, phase 3, non-inferiority TALENT study

Hao Wu1; Cheng Yao2; Tong Zhang1; Qingxia Zhao3; Weiping Cai4; Min Wang5; Hongzhou Lu6; Hui Wang7; Yuhuang Zheng8; Biao Zhu9; Jianhua Yu10; Yongtao Sun11; Min Zhao12; Wenhui Lun13; Wei Xia1; Qingshan Zheng14; Haiyan Peng15; Rongjian Lu16; Jianhua Hu17; Yiming Shao17; Meixia Wang18; Dong Xie19

1Department of Infectious Diseases, Beijing You’an Hospital, Capital Medical University, Beijing, China; 2Department of Clinical Development, Frontier Biotechnologies Co, Nanjing, China; 3Department of AIDS Control, Infectious Disease Hospital of Henan Province, Zhengzhou, China; 4Department of Infectious Diseases, The Eighth People’s Hospital of Guangzhou, Guangzhou, China; 5Department of AIDS Control, The First Hospital of Changsha, Changsha, China; 6Department of Infectious Diseases, Shanghai Public Health Clinical Center, Shanghai, China; 7Department of AIDS Control, The Third People’s Hospital of Shenzhen, Shenzhen, China; 8Department of AIDS Control, The Second Xiangya Hospital of Central South University, Changsha, China; 9Department of Infectious Diseases, The First Affiliated Hospital, Zhejiang University, Hangzhou, China; 10Department of AIDS Control, Xixi Hospital of Hangzhou, Hangzhou, China; 11Department of Infectious Diseases, Tangdu Hospital of The Fourth Military Medical University, Xian, China; 12Department of AIDS Control, 302 Military Hospital of China, Beijing, China; 13Department of AIDS Control, Beijing Ditan Hospital, Capital Medical University, Beijing, China; 14Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Biostatistics, Shanghai, China; 15Department of Clinical Operations, Beijing Co-CRO Medical Development Co, Ltd, Beijing, China; 16Department of Research and Development, Frontier Biotechnologies Co, Nanjing, China; 17Department of Virology, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China; 18Department of Clinical Research, Beijing You’an Hospital, Capital Medical University, Beijing, China; 19Department of Research and Development, Frontier Biotechnologies Co, Nanjing, China